000 01130 a2200337 4500
005 20250518011238.0
264 0 _c20190829
008 201908s 0 0 fre d
022 _a1773-0597
024 7 _a10.1016/j.jfo.2018.06.001
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aCallet, M
245 0 0 _a[Omalizumab for severe vernal keratoconjunctivitis].
_h[electronic resource]
260 _bJournal francais d'ophtalmologie
_cDec 2018
300 _ae499-e500 p.
_bdigital
500 _aPublication Type: Case Reports; Letter
650 0 4 _aAnti-Allergic Agents
_xtherapeutic use
650 0 4 _aChild
650 0 4 _aConjunctivitis, Allergic
_xdrug therapy
650 0 4 _aDrug Resistance
_xdrug effects
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aOmalizumab
_xpharmacology
650 0 4 _aSeverity of Illness Index
650 0 4 _aTreatment Outcome
700 1 _aStolowy, N
700 1 _aZanin, E
700 1 _aDenis, D
773 0 _tJournal francais d'ophtalmologie
_gvol. 41
_gno. 10
_gp. e499-e500
856 4 0 _uhttps://doi.org/10.1016/j.jfo.2018.06.001
_zAvailable from publisher's website
999 _c29087680
_d29087680